Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ifx-1

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    InflaRx Reports Q2 2024 Results And Provides Business Update
    InflaRx Reports Q2 2024 Results And Provides Business Update

    08 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/08/2926834/0/en/InflaRx-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    08 Aug 2024
    Share Share
    InflaRx Announces Initiation of its Commitment Program for GOHIBIC
    InflaRx Announces Initiation of its Commitment Program for GOHIBIC

    25 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/25/2816626/0/en/InflaRx-Announces-Initiation-of-its-Commitment-Program-for-GOHIBIC-vilobelimab-to-Help-Broaden-Access-for-Eligible-Patients.html

    GLOBENEWSWIRE
    25 Jan 2024
    Share Share
    InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab
    InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab

    06 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/11/06/2773976/0/en/InflaRx-Announces-First-Patient-Dosed-in-Phase-III-Trial-with-Vilobelimab-in-Pyoderma-Gangrenosum.html

    GLOBENEWSWIRE
    06 Nov 2023
    Share Share
    InflaRxs Marketing Authorization Application (MAA) for Vilobelimab
    InflaRxs Marketing Authorization Application (MAA) for Vilobelimab

    30 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/08/30/2734224/0/en/InflaRx-s-Marketing-Authorization-Application-MAA-for-Vilobelimab-for-Treatment-of-Critically-Ill-COVID-19-Patients-under-Review-by-European-Medicines-Agency-EMA.html

    GLOBENEWSWIRE
    30 Aug 2023
    Share Share
    InflaRx Announces Commercial Launch of Gohibic vilobelimab
    InflaRx Announces Commercial Launch of Gohibic vilobelimab

    21 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/21/2691860/0/en/InflaRx-Announces-Commercial-Launch-of-Gohibic-vilobelimab-in-the-U-S-for-the-Treatment-of-Critically-Ill-COVID-19-Patients.html

    GLOBENEWSWIRE
    21 Jun 2023
    Share Share
    InflaRx Receives FDA Emergency Use Authorization for Gohibic
    InflaRx Receives FDA Emergency Use Authorization for Gohibic

    04 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/04/2641171/0/en/InflaRx-Receives-FDA-Emergency-Use-Authorization-for-Gohibic-vilobelimab-for-Treatment-of-Critically-Ill-COVID-19-Patients.html

    GLOBENEWSWIRE
    04 Apr 2023
    Share Share